Abstract
Meningiomas are the most common primary brain tumors occurring primarily in elderly adults with a female preponderance. Meningiomas are classified into 15 histopathological subtypes occurring across three WHO grades (1–3). Majority meningiomas are benign grade 1 meningiomas. Up to 25% are of grade 2 histology and rarely are of grade 3 histology. They are postulated to arise from the arachnoid cap cells and can be classified broadly into two molecular subgroups that correlate with the sites of occurrence, histopathology, and outcome. The cerebral/cerebellar convexity and spinal meningiomas are driven by NF2 gene inactivation (22q monosomy and NF2 mutations) and commonly progress to higher grades (atypical and anaplastic meningiomas) with accumulation of additional cytogenetic (1p deletion, 14q deletion) and molecular alterations (CDKN2A/B deletions, TERT promoter mutations). Skull base meningiomas typically lack NF2 mutations and instead harbor mutations in TRAF7, AKT1, KLF4, SMO, SUFU, PIK3CA, and POLR2A genes, show Grade 1 histology, and do not usually progress to higher grades. However, they show higher rates of subtotal resection leading to frequent recurrences. Rarer aggressive histological subtypes such as clear cell meningiomas, rhabdoid meningiomas, and papillary meningiomas harbor germline or somatic mutations in SMARCE1, BAP1, and PBRM1 genes, respectively, and occur in younger age groups, and as part of familial tumor syndromes. Extent of resection and WHO grade are the most important prognostic variables. TERT promoter mutations, CDKN2A deletions, 1p deletion, and 14q deletion are molecular and cytogenetic alterations that correlate with poor prognosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Perry A, Louis DN, Budka H, von Deimling A, Sahm F, Rushing EJ, Mawrin C, Claus EB, Loeffler J, Sadetzki S. Meningioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system, revised. 4th ed. Lyon: IARC; 2016. p. 232–7.
Dalle Ore CL, Magill ST, Yen AJ, Shahin MN, Lee DS, Lucas CG, Chen WC, Viner JA, Aghi MK, Theodosopoulos PV, Raleigh DR, Villanueva-Meyer JE, McDermott MW. Meningioma metastases: incidence and proposed screening paradigm. J Neurosurg. 2019;5:1–9. https://doi.org/10.3171/2019.1.JNS181771.
Kakkar A, Kumar A, Das A, Pathak P, Sharma MC, Singh M, Suri A, Sarkar C, Suri V. 1p/14q co-deletion: a determinant of recurrence in histologically benign meningiomas. Indian J Pathol Microbiol. 2015;58(4):433–8.
Peyre M, Gaillard S, de Marcellus C, et al. Progestin-associated shift of meningioma mutational landscape. Ann Oncol. 2018;29(3):681–6.
Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol. 2015;130(3):441–3.
Gautagny S, Nault JC, Mallet M, et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24(2):184–9.
Perry A, Scheithauer BW, Stafford SL, et al. “Malignancy” in meningioms: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999;85(9):2046–56.
Gabeau-Lacet D, Aghi M, Betensky RA, Barker FG, Loeffler JS, Louis DN. Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg. 2009;111(3):464–71.
Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 2017;18(5):682–94.
Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 2018;135(6):955–63.
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kiliç T, Lifton RP, Noonan JP, Yasuno K, Günel M. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013;339(6123):1077–80.
Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013;45(3):285–9.
Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, Perry A, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G. International consortium on meningiomas. Molecular and translational advances in meningiomas. Neuro-Oncology. 2019;21(Suppl 1):i4–i17. https://doi.org/10.1093/neuonc/noy178.
Lee YS, Lee YS. Molecular characteristics of meningiomas. J Pathol Transl Med. 2020;54(1):45–63.
Juratli TA, McCabe D, Nayyar N, Williams EA, Silverman IM, Tummala SS, Fink AL, Baig A, Martinez-Lage M, Selig MK, Bihun IV, Shankar GM, Penson T, Lastrapes M, Daubner D, Meinhardt M, Hennig S, Kaplan AB, Fujio S, Kuter BM, Bertalan MS, Miller JJ, Batten JM, Ely HA, Christiansen J, Baretton GB, Stemmer-Rachamimov AO, Santagata S, Rivera MN, Barker FG 2nd, Schackert G, Wakimoto H, Iafrate AJ, Carter SL, Cahill DP, Brastianos PK. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018;136(5):779–92.
Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, Mamatjan Y, Klironomos G, Gonen L, Au K, Mansouri S, Karimi S, Sahm F, von Deimling A, Taylor MD, Laperriere NJ, Pugh TJ, Aldape KD, Zadeh G. Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. Nat Commun. 2017;8(1):186.
Williams EA, Wakimoto H, Shankar GM, Barker FG 2nd, Brastianos PK, Santagata S, Sokol ES, Pavlick DC, Shah N, Reddy A, Venstrom JM, Alexander BM, Ross JS, Cahill DP, Ramkissoon SH, Juratli TA. Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol. 2020;140(1):89–93.
Battu S, Kumar A, Pathak P, Purkait S, Dhawan L, Sharma MC, Suri A, Singh M, Sarkar C, Suri V. Clinicopathological and molecular characteristics of pediatric meningiomas. Neuropathology. 2018;38(1):22–33.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Nambirajan, A., Singh, J., Suri, V. (2021). Pathology and Molecular Pathology of Meningioma. In: Mallick, S., Giridhar, P., Rath, G.K. (eds) Evidence based practice in Neuro-oncology. Springer, Singapore. https://doi.org/10.1007/978-981-16-2659-3_5
Download citation
DOI: https://doi.org/10.1007/978-981-16-2659-3_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-2658-6
Online ISBN: 978-981-16-2659-3
eBook Packages: MedicineMedicine (R0)